SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis
Key facts
- Who runs it
- Samsung Medical Center
- Where
- South Korea11 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT07944066
- KCT0012093
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 1,182 people, planned
- Started
- 10 Jun 2026
- Expected to end
- Jun 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Enavogliflozin
- Placebo
- Record updated
- 18 November 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Able to understand the study protocol and provide written informed consent
- Adults aged 19 years or older
- Moderate or asymptomatic severe aortic stenosis, defined as all of the following:
- Aortic valve area (AVA) less than 1.5 cm2, aortic valve peak velocity (Vmax) 3 m/s or higher, or aortic valve mean pressure gradient 25 mmHg or higher
- Left ventricular ejection fraction 50% or higher
- Asymptomatic, New York Heart Association (NYHA) functional class I
Who cannot take part
- Severe stenosis or regurgitation of another valve, or concomitant severe aortic regurgitation
- Use of an SGLT2 inhibitor within the previous 3 months
- Participation in another clinical trial within the previous 1 month or 5 half-lives of the investigational product
- Known hypersensitivity to SGLT2 inhibitors
- Type 1 diabetes mellitus
- Left ventricular ejection fraction below 50%
- Liver disease with AST or ALT 2 or more times the upper limit of normal, or history of hepatic encephalopathy, esophageal varices, or portosystemic shunt
- Current use of medications that may affect efficacy assessment (DPP-4 inhibitors, vitamin K, calcium supplements)
- Indication for aortic valve intervention according to current ACC/AHA or ESC/EACTS guidelines
- Symptomatic severe aortic stenosis
- Very severe aortic stenosis (aortic valve Vmax 5 m/s or higher, or mean pressure gradient 50 mmHg or higher)
- NYHA functional class II to IV
- Estimated glomerular filtration rate below 30 mL/min/1.73 m2, or on dialysis
- Pregnancy or breastfeeding
- Life expectancy below 2 years, or inability to comply with the study protocol
- Diabetic ketoacidosis
- Sexually active women of childbearing potential who do not agree to use adequate contraception during the study
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidative-stress pathways that drive valve calcification. A recent observational study reported slower AS progression in patients treated with SGLT2 inhibitors.
Read full original descriptionShow less
SAVE-AS is a multicenter, prospective, randomized, double-blind, placebo-controlled, investigator-initiated superiority trial testing whether the SGLT2 inhibitor enavogliflozin (0.3 mg once daily) reduces the composite of all-cause death, aortic valve replacement, and hospitalization for heart failure in adults with asymptomatic moderate or severe aortic stenosis and preserved left ventricular ejection fraction (50% or higher). A total of 1,182 participants at 11 centers in the Republic of Korea will be randomized 1:1 to enavogliflozin or matching placebo, stratified by participating center and AS severity (moderate vs severe). Study treatment is given for 24 months, with follow-up visits at 2, 6, 12, 18, and 24 months and an end-of-treatment assessment at 25 months. Secondary outcomes include the individual components of the primary composite, cardiac death, echocardiographic AS severity, left ventricular mass, global longitudinal strain and ejection fraction, NT-proBNP, annual eGFR slope, and SGLT2 inhibitor-related adverse events. All clinical events are adjudicated by an independent clinical event adjudication committee, and safety is overseen by an independent data and safety monitoring board.
The 2 groups in the trial
- EnavogliflozinTreatment being tested
Enavogliflozin 0.3 mg film-coated tablet orally once daily for 24 months, in addition to guideline-directed medical therapy.
- PlaceboPlacebo, for comparison
Matching placebo tablet (identical in appearance) orally once daily for 24 months, in addition to guideline-directed medical therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Assess the Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitor in Patients With Aortic Valve Stenosis: SAVE-AS (SGLT2i Assessment Valvular Effect in AS)
- Record updated
- 18 November 2026